Tags

Type your tag names separated by a space and hit enter

Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Neurodegener Dis Manag. 2018 06; 8(3):151-159.ND

Abstract

AIM

To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray.

METHODS

Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias.

RESULTS

ADL was maintained or slightly improved with THC:CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC:CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC:CBD oromucosal spray had a positive global impression of change during treatment.

CONCLUSION

In this pilot study, THC:CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted.

Links

  • Publisher Full Text

    • Authors+Show Affiliations

    Mallada Frechín J
    Unidad de Neurología, Hospital General de Elda, Elda (Alicante), Spain.

    MeSH

    Activities of Daily LivingAdultCannabidiolDronabinolDrug CombinationsDrug Delivery SystemsFemaleHumansMaleMiddle AgedMultiple SclerosisMuscle SpasticityOral SpraysRetrospective StudiesStatistics, NonparametricTreatment Outcome

    Pub Type(s)

    Journal Article
    Observational Study
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    29851356

    Citation

    Mallada Frechín, Javier. "Effect of Tetrahydrocannabinol:cannabidiol Oromucosal Spray On Activities of Daily Living in Multiple Sclerosis Patients With Resistant Spasticity: a Retrospective, Observational Study." Neurodegenerative Disease Management, vol. 8, no. 3, 2018, pp. 151-159.
    Mallada Frechín J. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. Neurodegener Dis Manag. 2018;8(3):151-159.
    Mallada Frechín, J. (2018). Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. Neurodegenerative Disease Management, 8(3), 151-159. https://doi.org/10.2217/nmt-2017-0055
    Mallada Frechín J. Effect of Tetrahydrocannabinol:cannabidiol Oromucosal Spray On Activities of Daily Living in Multiple Sclerosis Patients With Resistant Spasticity: a Retrospective, Observational Study. Neurodegener Dis Manag. 2018;8(3):151-159. PubMed PMID: 29851356.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. A1 - Mallada Frechín,Javier, Y1 - 2018/05/31/ PY - 2018/6/1/pubmed PY - 2019/1/3/medline PY - 2018/6/1/entrez KW - THC:CBD oromucosal spray KW - activities of daily living KW - multiple sclerosis KW - spasticity SP - 151 EP - 159 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 8 IS - 3 N2 - AIM: To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray. METHODS: Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias. RESULTS: ADL was maintained or slightly improved with THC:CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC:CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC:CBD oromucosal spray had a positive global impression of change during treatment. CONCLUSION: In this pilot study, THC:CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/29851356/Effect_of_tetrahydrocannabinol:cannabidiol_oromucosal_spray_on_activities_of_daily_living_in_multiple_sclerosis_patients_with_resistant_spasticity:_a_retrospective_observational_study_ L2 - http://www.futuremedicine.com/doi/full/10.2217/nmt-2017-0055?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -